SCHEMBL2897115

SCHEMBL2897115

COC(=O)NC1CCCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.62
CA2 P00918 2/20 0.62
USP30 Q70CQ3 3/20 0.56
EPHX1 P07099 1/20 0.55
HSD11B1 P28845 4/20 0.51
CYP2C9 P11712 1/20 0.51
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
HDAC4 P56524 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
PARP1 P09874 1/20 0.48
FPR3 P25089 1/20 0.48
FPR2 P25090 1/20 0.48
CTSK P43235 2/20 0.47
HPGD P15428 1/20 0.47
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
CNR1 P21554 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28767041 1.00 CA1 (0.62) CA1CA2USP30EPHX1HSD11B1
SCHEMBL27694125 1.00 CA1 (0.62) CA1CA2USP30EPHX1HSD11B1
SCHEMBL17545919 0.93 CA1 (0.71) CA1CA2USP30EPHX1HSD11B1
SCHEMBL1782544 0.91 HSD11B1 (0.60) CA1CA2USP30EPHX1HSD11B1
SCHEMBL22680068 0.91 HSD11B1 (0.60) CA1CA2USP30EPHX1HSD11B1
SCHEMBL2037731 0.91 HSD11B1 (0.60) CA1CA2USP30EPHX1HSD11B1
SCHEMBL24756014 0.89 CA1 (0.70) CA1CA2USP30EPHX1HSD11B1
SCHEMBL21222018 0.89 CA1 (0.70) CA1CA2USP30EPHX1HSD11B1
SCHEMBL23555724 0.88 EPHX1 (0.69) CA1CA2USP30EPHX1HSD11B1
SCHEMBL20986600 0.87 CA1 (0.52) CA1CA2USP30EPHX1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 CA1 1467/4885CA2 680/4885USP30 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.